ES440110A1 - Procedimiento para la obtencion de compuestos esteroides cardiotonicos. - Google Patents

Procedimiento para la obtencion de compuestos esteroides cardiotonicos.

Info

Publication number
ES440110A1
ES440110A1 ES440110A ES440110A ES440110A1 ES 440110 A1 ES440110 A1 ES 440110A1 ES 440110 A ES440110 A ES 440110A ES 440110 A ES440110 A ES 440110A ES 440110 A1 ES440110 A1 ES 440110A1
Authority
ES
Spain
Prior art keywords
formula
see formula
groups
hydrogen
esterified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES440110A
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siphar SA
Original Assignee
Siphar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siphar SA filed Critical Siphar SA
Publication of ES440110A1 publication Critical patent/ES440110A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES440110A 1974-08-08 1975-08-08 Procedimiento para la obtencion de compuestos esteroides cardiotonicos. Expired ES440110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1085574A CH621803A5 (enExample) 1974-08-08 1974-08-08

Publications (1)

Publication Number Publication Date
ES440110A1 true ES440110A1 (es) 1977-02-16

Family

ID=4367535

Family Applications (1)

Application Number Title Priority Date Filing Date
ES440110A Expired ES440110A1 (es) 1974-08-08 1975-08-08 Procedimiento para la obtencion de compuestos esteroides cardiotonicos.

Country Status (12)

Country Link
US (1) US4000125A (enExample)
JP (1) JPS5141372A (enExample)
AR (1) AR217617A1 (enExample)
BE (1) BE832271A (enExample)
CA (1) CA1049499A (enExample)
CH (1) CH621803A5 (enExample)
DE (1) DE2534981A1 (enExample)
DK (1) DK139101B (enExample)
ES (1) ES440110A1 (enExample)
FR (1) FR2281124A1 (enExample)
GB (1) GB1484655A (enExample)
SE (1) SE418401B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144136B (it) * 1980-03-05 1986-10-29 Zenyaku Kogyo Kk Glucosidi di condurango agenti antitumorali che li comprendono e procedimento per la loro preparazione
US5373095A (en) * 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
IT1262931B (it) * 1992-01-16 1996-07-22 Zambon Spa Composti steroidei 17(piridazin-n-ossido)-sostituiti attivi sul sistema cardiovascolare
DE4227616C2 (de) * 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
PL1853619T3 (pl) * 2005-03-02 2011-03-31 Univ Maryland 3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2461814A4 (en) 2009-08-07 2012-12-05 Tokai Pharmaceuticals Inc PROSTATE CANCER TREATMENT
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US11053279B2 (en) * 2015-06-29 2021-07-06 Universiteit Gent Methods for the site-selective coupling of a first agent to a second agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838163A (en) * 1968-11-22 1974-09-24 Hoffmann La Roche Substituted isoxazole derivatives as steroid intermediates

Also Published As

Publication number Publication date
JPS5141372A (enExample) 1976-04-07
CH621803A5 (enExample) 1981-02-27
DK139101B (da) 1978-12-18
US4000125A (en) 1976-12-28
CA1049499A (en) 1979-02-27
BE832271A (fr) 1975-12-01
SE7508908L (sv) 1976-02-09
AR217617A1 (es) 1980-04-15
GB1484655A (en) 1977-09-01
FR2281124B1 (enExample) 1980-05-16
SE418401B (sv) 1981-05-25
DE2534981A1 (de) 1976-02-19
DK358875A (enExample) 1976-02-09
DK139101C (enExample) 1979-05-21
FR2281124A1 (fr) 1976-03-05

Similar Documents

Publication Publication Date Title
ES440110A1 (es) Procedimiento para la obtencion de compuestos esteroides cardiotonicos.
Stevens et al. Elaiomycin. 1 an aliphatic α, β-unsaturated azoxy compound
ES366943A1 (es) Procedimiento para la preparacion de derivados de 1-etil-3,3-dimetil-ciclohexano.
SE323866B (enExample)
Ziegler The elucidation of the structure of hyocholic acid
ES301833A1 (es) Un procedimiento para la prepación de 19-alkil-esteroides
ES408274A1 (es) Procedimiento para la preparacion de 2-(furilmetil)-6,7- benzomorfanos.
ES429020A1 (es) Procedimiento para preparar nuevos derivados de tiazol-5- metanol.
GB845649A (en) 6-deoxytetracycline and 6-deoxyoxytetracycline
US2320847A (en) delta 5-cholestenone-3 and a method for producing the same
Seta et al. Biochemical Studies on “Bakanae” Fungus. Part 45: Chemical Structure of Gibberellins. Part XII
ES435204A1 (es) Procedimiento para la preparacion de 11beta -fluor-andros- tenos.
ES382660A1 (es) Procedimiento para la obtencion de derivados de rifamicina s y sv.
ES405648A1 (es) Procedimiento para la preparacion de nuevos acidos 4 - (4 -bifenilil) - 4 - hidroxi - butiricos, sus esteres o lacto- nas.
Wolfrom et al. Degradative studies on streptomycin
ES384331A1 (es) Procedimiento para la obtencion de 6 alfa-metil-19-nor- progesterona.
ES421790A1 (es) Procedimiento de preparacion de derivados del acido prosta-noico.
Sugiyama et al. The Photoreaction of p-Substituted β-Benzoylacrylic Acids
ES376027A1 (es) Un procedimiento para la preparacion de nuevos 3-desoxo-19-nor-esteroides.
ES264431A1 (es) Un procedimiento para la preparación de esteroides
ES376501A1 (es) Procedimiento de preparacion de nuevos acetales ciclicos derivados del pregnano.
ES326845A1 (es) Procedimiento de fabricacion de derivados de 1-hidroxiestradiol.
ES416165A1 (es) Procedimiento de fabricacion de un derivado del pirazol.
ES393800A1 (es) Un procedimiento para la preparacion de penicilin-1-oxidos.
ES307162A1 (es) Un procedimiento de sintesis de derivados esteroides.